Patient recommendations for reducing long-lasting economic burden after breast cancer

Lorraine Dean, Shadiya L. Moss, Sarah I. Rollinson, Livia Frasso Jaramillo, Raheem J. Paxton, Jill Owczarzak

Research output: Contribution to journalArticle

Abstract

Background: In the United States, patients who have breast cancer experience significant economic burden compared with those who have other types of cancers. Cancer-related economic burden is exacerbated by adverse treatment effects. Strategies to resolve the economic burden caused by breast cancer and its adverse treatment effects have stemmed from the perspectives of health care providers, oncology navigators, and other subject-matter experts. For the current study, patient-driven recommendations were elicited to reduce economic burden after 1) breast cancer and 2) breast cancer-related lymphedema, which is a common, persistent adverse effect of breast cancer. Methods: Qualitative interviews were conducted with 40 long-term breast cancer survivors who were residents of Pennsylvania or New Jersey in 2015 and were enrolled in a 6-month observational study. Purposive sampling ensured equal representation by age, socioeconomic position, and lymphedema diagnosis. Semistructured interviews addressed economic challenges, supports used, and patient recommendations for reducing financial challenges. Interviews were coded, and representative quotes from the patient recommendations were analyzed and reported to illustrate key findings. Results: Of 40 interviewees (mean age, 64 years; mean time since diagnosis, 12 years), 27 offered recommendations to reduce the economic burden caused by cancer and its adverse treatment effects. Nine recommendations emerged across 4 major themes: expanding affordable insurance and insurance-covered items, especially for lymphedema treatment (among the 60% who reported lymphedema); supportive domestic help; financial assistance from diagnosis through treatment; and employment-preserving policies. Conclusions: The current study yielded 9 actionable, patient-driven recommendations—changes to insurance, supportive services, financial assistance, and protective policies—to reduce breast cancer-related economic burden. These recommendations should be tested through policy and programmatic interventions.

Original languageEnglish (US)
JournalCancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Economics
Breast Neoplasms
Lymphedema
Insurance
Interviews
Patient Advocacy
Therapeutics
Neoplasms
Health Personnel
Observational Studies
Survivors

Keywords

  • breast cancer
  • economic burden
  • lymphedema
  • qualitative analysis
  • United States

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Patient recommendations for reducing long-lasting economic burden after breast cancer. / Dean, Lorraine; Moss, Shadiya L.; Rollinson, Sarah I.; Frasso Jaramillo, Livia; Paxton, Raheem J.; Owczarzak, Jill.

In: Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Dean, Lorraine ; Moss, Shadiya L. ; Rollinson, Sarah I. ; Frasso Jaramillo, Livia ; Paxton, Raheem J. ; Owczarzak, Jill. / Patient recommendations for reducing long-lasting economic burden after breast cancer. In: Cancer. 2019.
@article{5527e172053046e58b21116d621a88f2,
title = "Patient recommendations for reducing long-lasting economic burden after breast cancer",
abstract = "Background: In the United States, patients who have breast cancer experience significant economic burden compared with those who have other types of cancers. Cancer-related economic burden is exacerbated by adverse treatment effects. Strategies to resolve the economic burden caused by breast cancer and its adverse treatment effects have stemmed from the perspectives of health care providers, oncology navigators, and other subject-matter experts. For the current study, patient-driven recommendations were elicited to reduce economic burden after 1) breast cancer and 2) breast cancer-related lymphedema, which is a common, persistent adverse effect of breast cancer. Methods: Qualitative interviews were conducted with 40 long-term breast cancer survivors who were residents of Pennsylvania or New Jersey in 2015 and were enrolled in a 6-month observational study. Purposive sampling ensured equal representation by age, socioeconomic position, and lymphedema diagnosis. Semistructured interviews addressed economic challenges, supports used, and patient recommendations for reducing financial challenges. Interviews were coded, and representative quotes from the patient recommendations were analyzed and reported to illustrate key findings. Results: Of 40 interviewees (mean age, 64 years; mean time since diagnosis, 12 years), 27 offered recommendations to reduce the economic burden caused by cancer and its adverse treatment effects. Nine recommendations emerged across 4 major themes: expanding affordable insurance and insurance-covered items, especially for lymphedema treatment (among the 60{\%} who reported lymphedema); supportive domestic help; financial assistance from diagnosis through treatment; and employment-preserving policies. Conclusions: The current study yielded 9 actionable, patient-driven recommendations—changes to insurance, supportive services, financial assistance, and protective policies—to reduce breast cancer-related economic burden. These recommendations should be tested through policy and programmatic interventions.",
keywords = "breast cancer, economic burden, lymphedema, qualitative analysis, United States",
author = "Lorraine Dean and Moss, {Shadiya L.} and Rollinson, {Sarah I.} and {Frasso Jaramillo}, Livia and Paxton, {Raheem J.} and Jill Owczarzak",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/cncr.32012",
language = "English (US)",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Patient recommendations for reducing long-lasting economic burden after breast cancer

AU - Dean, Lorraine

AU - Moss, Shadiya L.

AU - Rollinson, Sarah I.

AU - Frasso Jaramillo, Livia

AU - Paxton, Raheem J.

AU - Owczarzak, Jill

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: In the United States, patients who have breast cancer experience significant economic burden compared with those who have other types of cancers. Cancer-related economic burden is exacerbated by adverse treatment effects. Strategies to resolve the economic burden caused by breast cancer and its adverse treatment effects have stemmed from the perspectives of health care providers, oncology navigators, and other subject-matter experts. For the current study, patient-driven recommendations were elicited to reduce economic burden after 1) breast cancer and 2) breast cancer-related lymphedema, which is a common, persistent adverse effect of breast cancer. Methods: Qualitative interviews were conducted with 40 long-term breast cancer survivors who were residents of Pennsylvania or New Jersey in 2015 and were enrolled in a 6-month observational study. Purposive sampling ensured equal representation by age, socioeconomic position, and lymphedema diagnosis. Semistructured interviews addressed economic challenges, supports used, and patient recommendations for reducing financial challenges. Interviews were coded, and representative quotes from the patient recommendations were analyzed and reported to illustrate key findings. Results: Of 40 interviewees (mean age, 64 years; mean time since diagnosis, 12 years), 27 offered recommendations to reduce the economic burden caused by cancer and its adverse treatment effects. Nine recommendations emerged across 4 major themes: expanding affordable insurance and insurance-covered items, especially for lymphedema treatment (among the 60% who reported lymphedema); supportive domestic help; financial assistance from diagnosis through treatment; and employment-preserving policies. Conclusions: The current study yielded 9 actionable, patient-driven recommendations—changes to insurance, supportive services, financial assistance, and protective policies—to reduce breast cancer-related economic burden. These recommendations should be tested through policy and programmatic interventions.

AB - Background: In the United States, patients who have breast cancer experience significant economic burden compared with those who have other types of cancers. Cancer-related economic burden is exacerbated by adverse treatment effects. Strategies to resolve the economic burden caused by breast cancer and its adverse treatment effects have stemmed from the perspectives of health care providers, oncology navigators, and other subject-matter experts. For the current study, patient-driven recommendations were elicited to reduce economic burden after 1) breast cancer and 2) breast cancer-related lymphedema, which is a common, persistent adverse effect of breast cancer. Methods: Qualitative interviews were conducted with 40 long-term breast cancer survivors who were residents of Pennsylvania or New Jersey in 2015 and were enrolled in a 6-month observational study. Purposive sampling ensured equal representation by age, socioeconomic position, and lymphedema diagnosis. Semistructured interviews addressed economic challenges, supports used, and patient recommendations for reducing financial challenges. Interviews were coded, and representative quotes from the patient recommendations were analyzed and reported to illustrate key findings. Results: Of 40 interviewees (mean age, 64 years; mean time since diagnosis, 12 years), 27 offered recommendations to reduce the economic burden caused by cancer and its adverse treatment effects. Nine recommendations emerged across 4 major themes: expanding affordable insurance and insurance-covered items, especially for lymphedema treatment (among the 60% who reported lymphedema); supportive domestic help; financial assistance from diagnosis through treatment; and employment-preserving policies. Conclusions: The current study yielded 9 actionable, patient-driven recommendations—changes to insurance, supportive services, financial assistance, and protective policies—to reduce breast cancer-related economic burden. These recommendations should be tested through policy and programmatic interventions.

KW - breast cancer

KW - economic burden

KW - lymphedema

KW - qualitative analysis

KW - United States

UR - http://www.scopus.com/inward/record.url?scp=85062496779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062496779&partnerID=8YFLogxK

U2 - 10.1002/cncr.32012

DO - 10.1002/cncr.32012

M3 - Article

C2 - 30839106

AN - SCOPUS:85062496779

JO - Cancer

JF - Cancer

SN - 0008-543X

ER -